Outlook Therapeutics, Inc. — Director's Dealing 2017

Nov 2, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncobiologics, Inc. (ONS)
CIK: 0001649989
Period of Report: 2017-10-31

Reporting Person: Thomas Joe (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-10-31	Stock Option (Right to Buy)	$1.26	A	25000	Acquired	2027-10-31	Common Stock (25000)	Direct

Footnotes

F1: 33.33% of the shares underlying the option shall vest on each of the first, second and third anniversaries of the grant date, such that 100% of the shares underlying the option shall be vested on October 31, 2020, subject to the Reporting Person providing continued service through such date.